Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HALTED $$$$$$$$%$$$
Odyssey Health, Inc selling approx 17k shrs...have 715k shrs left post rs....could be tax reasons?...imao...r
Was a big mover this morning. I about 130K shares and am now $2.5K down. This may be my Big Beautiful Loss of the year,
From latest 10q and with $4mil in financing since... "The Company believes its working capital at September 30, 2024 will be sufficient to meet the business objectives as presently structured only through the fourth quarter of 2024. As such, there is substantial doubt that we can continue as a going concern beyond that date."...they burn thru $2.5-$3mil per quarter now b4 the trial starts...something gotta give...i'm not a hater by any means...imao..r
Obviously the 10k said something about needing more capital
What else is new clinical stage med tech land
Sooner or later they will need to do a RS…just a question if b4 or after the start of phase 2a trial announcement…running out of time to get over a buck … and they need funding if you read the 10k…imao…r
OGEN: I lost--my-shirt today, behind this catastrophic 'fire storm' event!! (Can Trump please do a FLY-OVER to assess the damage --- and then otherwise do a Federal-Bailout for ME???!!!)
How did this not get halted today. Obvious P & D
They got me me fortunately only put 700 in it. So dumb to chase these turds
Well Trump is here to help Day Traders. This could get ugly.
OGEN: I'm ashamed to admit this, but I grabbed $3K worth of this at $0.57 in the Pre-Market today --- totally abandoning my standard practice of seeing if it 'HAS ANY LEGS' in the Open-Market today. (To paraphrase one of the Orion's Board's legendary Founding Fathers --- 'Monk', or 'Augusta'??)
I'm PRAYING hard right now --- see ME below, live --- for circa $1.50 here, a little later today. (Heck, whatever WORKS --- right??)
OGEN..................................https://stockcharts.com/h-sc/ui?s=OGEN&p=W&b=5&g=0&id=p86431144783
OGEN: Unusual PR here ---
https://finance.yahoo.com/news/oragenics-inc-chief-medical-officer-131500235.html
Obviously, they are trying to exploit & capitalize upon the NFL fears of BRAIN injuries:
"advancing innovative treatments for concussion and brain-related health conditions"
OGEN: Hot-off-the-PRESS!!! What kind of news is this???!!!
"Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025"
OGEN: And all behind NOT DUMPING MORE SHARES, purported "news".
The best premarket runner .59 + 107%
I have various scans set up to alert me…🥳
Curious as to how would've you been alerted to this when at 4:00`, it closed at .325 down .01 ?
Who's excited...🥳...its just a flip...
Don't get too excited, purely a manipulation (hence aftermarket) by Dawson James to do a financing, I'm sure you'll see the 8k tomorrow or Friday. JMHO
Oragenics Inc. ($OGEN) is a healthcare innovator focusing on novel antibiotics and treatments for oral mucositis. With a 52-week range of $0.86 to $7.74, it is advancing products like OG716, LBPs, and Terra CoV-2 immunization.
WOW more weak hands. And with only 5.6 mil os :)
The average one-year price target for Oragenics, Inc. is $91.80. :)
Weak many hands are gone, new investors welcome. :)
Weak many hands are gone, new investors welcome. :)
Not for long. :)
News just hit! Oragenics Issues Update to Shareholders:
https://www.otcmarkets.com/stock/OGEN/news/story?e&id=2676834
Will this turd float to the surface? :)
Don't madder they will short it down to nothing
Chart setup perfectly here -> time is koming for the super spike
https://stockcharts.com/h-sc/ui?s=ogen
Hey whatever it takes to see it rise to the moon but wow hats off to your sacrifice. :)
3/22 Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
"“We are thrilled to have begun this pivotal study with Frontage, a premier drug development contract research organization, and are thankful to the acceleration Frontage has offered our important IND-enabling study. We believe the results from this rabbit toxicology study will support our development strategy for our intranasal COVID-19 vaccine candidate, NT-CoV2-1. The intranasal delivery route is particularly relevant as it may further reduce transmission of the virus and provide a needle-free delivery option. The findings from this preclinical toxicology study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration,” said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics."
https://ir.oragenics.com/press-releases/detail/142
KABOOM !! ve got movement!!
Looks like word is getting out. :)
I agree. The buy consensus is at 83%.3 days ago. I think info is near. :)
Followers
|
78
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
866
|
Created
|
01/29/13
|
Type
|
Free
|
Moderators |
President and Chief Executive Officer
Dr. Joslyn was a partner in Lazarus Pharmaceuticals. Prior to that he served as the Chief Executive Officer and Director of several privately held companies including Edusa Pharmaceuticals and Sentinella Pharmaceuticals and prior to that he was the Senior Vice-President Research and Development of Penwest Pharmaceuticals and also held senior drug development positions with Johnson & Johnson.
Chief Financial Officer
Mr. Sullivan has served as our interim principal executive officer since October 30, 2014 and served as our Chief Financial Officer, Secretary and Treasurer since February 6, 2012. Mr. Sullivan has held senior level financial positions for several publicly and privately held businesses including Utek Corporation, eANGLER, and HSN Direct International Limited. Most recently, he was the Group Financial Officer for the Investigative Services and Litigation Consulting Services segment of First Advantage Corporation. Mr. Sullivan is a Florida Certified Public Accountant. He graduated from the Florida State University with a Bachelor of Science in Accounting and a Master of Business Administration.
Senior Vice President of Discovery Research
Dr. Handfield is, the Company’s Senior Vice President of Discovery Research and previously has served as our Director of Research and Development. Prior to joining our Company, Dr. Handfield held a position as Tenured Associate Professor at the Center for Molecular Microbiology and the Department of Oral Biology at the University of Florida College of Dentistry, where he co-invented IVIAT and co-founded ivi Gene Corp. and Epicure Corp. to commercialize this and related technologies. Dr. Handfield holds a B.S. degree in Biochemistry, and a MS degree and PhD in Microbiology and Immunology from the Université Laval College of Medicine in Canada, and did postdoctoral training at the University of Florida.
January 7, 2021
December 29, 2020
December 24, 2020
November 24, 2020
November 20, 2020
November 19, 2020
October 6, 2020
September 28, 2020
September 11, 2020
August 20, 2020
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |